Home » ADVANCIS PHARMACEUTICAL COMPLETES ENROLLMENT IN AMOXICILLIN PULSYS PHASE III TRIAL
ADVANCIS PHARMACEUTICAL COMPLETES ENROLLMENT IN AMOXICILLIN PULSYS PHASE III TRIAL
Advancis Pharmaceutical Corporation (Nasdaq: AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced that it has completed enrollment in the Company's Amoxicillin PULSYS Phase III clinical trial for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-01-2006/0004372095&EDATE=)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May